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The Editorial on the Research Topic
Combination Strategies in the Treatment of Melanoma
The successful treatment of melanoma was considered a significant challenge by oncologists for 
many years. However, this situation changed in 2011 with the approval of two novel agents, the 
anti-CTLA4 monoclonal antibody, ipilimumab, and the BRAF inhibitor, vemurafenib. These 
two drugs completely changed the management of metastatic melanoma and, for the first time, 
it became possible to significantly improve overall survival. More new therapies have followed, 
including other targeted agents (e.g., MEK inhibitors) and immunotherapies (e.g., anti-PD-1 
agents). The availability of these new agents has resulted in a focus on combination strategies 
aimed at improving outcomes still further. Novel combinations of targeted drugs and/or immuno-
therapies represent the future treatment not only for melanoma but also for all solid tumors. The 
articles collected together in this Research Topic discuss various aspects of the use combination 
strategies in melanoma management.
Inhibition of angiogenesis through the targeting of vascular endothelial growth factor (VEGF) 
has been used in the treatment of cancer for many years, although the mechanisms of its antitumor 
activity remain poorly understood. More recently, the advent of immune checkpoint inhibition (e.g., 
ipilimumab and nivolumab) has led to a better understanding of the possible effects of immunother-
apy on immune-mediated vasculopathy in the tumor, with the suggestion that the tumor vasculature 
may be an important interface between the tumor-directed immune response and the cancer itself. 
Initial studies of the relationship between angiogenesis, VEGF signaling and the immune system 
suggest that the combination of immune checkpoint blockade with VEGF inhibition has potential. 
The rationale for combined angiogenesis inhibition and immune checkpoint inhibition is reviewed 
by Ott et al. Clinical studies of combined immunotherapy and VEGF inhibition, e.g., ipilimumab 
plus bevacizumab, are ongoing and represent a potentially promising approach for cancer treatment.
The use of combined BRAF and MEK inhibition in advanced melanoma in order to overcome 
resistance and reduce toxicity is reviewed by McArthur, who notes that the impact of pathway 
inhibition in the adjuvant setting, where there can be differences in the extent of response of micro-
metastases or in the microenvironment that emerges following treatment, necessitates ongoing 
preclinical and clinical research into therapeutic targeting of the pathway. Combination approaches 
that look at simultaneous or sequential use of immunotherapeutic approaches with agents that target 
the RAF/MEK/ERK pathway are also a priority, with evidence suggesting that targeted therapies can 
sensitize tumor cells to immune attacks and improve the effector function of immune cells, but it 
should not divert attention away from the pathway that induces such profound oncogene addiction 
in melanoma patients whose tumors contain activating mutations in BRAF.
New treatment strategies that target key effectors of the RAF/MEK/ERK pathway may display 
intrinsic or acquired resistance. Evidence suggests that inhibition of a single effector involved 
in melanoma pathogenesis may be ineffective in blocking tumor growth. As such, a better 
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understanding of the multiple molecular alterations accounting 
for either response or resistance to treatments with targeted 
inhibitors may be useful in identifying which combination strat-
egies are likely to be the most effective. In their paper, Palmieri 
et al. summarize the known molecular mechanisms underlying 
intrinsic and acquired drug resistance and highlight the need for 
strategies that combine the most effective targeted treatments 
with cancer immunotherapies.
Resistance to BRAF and MEK inhibitors can be mediated 
by activation of the PI3K pathway, providing a strong rationale 
for combination therapy in melanoma. Original research by 
Sweetlove et  al. investigated the effects of a MEK inhibitor 
(selumetinib)and a BRAF inhibitor (vemurafenib) alone and in 
combination with inhibitors of pan-PI3K (ZSTK474), pan-PI3K/
mTOR (BEZ235), individual PI3K isoforms (p110α, A66; p110β, 
TGX-221; p110γ, AS-252424; p110δ, idelalisib), or mTORC1/2 
(KU-0063794) on nine metastatic BRAF-mutated melanoma 
cell lines. Selumetinib and vemurafenib potently inhibited cell 
proliferation in all cell lines, especially in those that expressed 
low levels of phosphorylated AKT (pAKT). Pan-PI3K and pan-
PI3K/mTOR inhibitors also inhibited cell proliferation in all cell 
lines and enhanced the antitumor activity of selumetinib and 
vemurafenib in the majority of lines. These results suggest that 
the sensitivity of BRAF-mutant melanoma cells to BRAF or MEK 
inhibitors is at least partly mediated by activation of the PI3K 
pathway and can be enhanced by combined inhibition of the 
BRAF/MEK and PI3K/mTOR signaling pathways.
Neuropilin-1 (NRP-1) is a transmembrane glycoprotein that 
acts as a coreceptor for various members of the VEGF family. Its 
ability to bind or modulate the activity of a number of other extra-
cellular ligands has suggested involvement in a variety of physi-
ological and pathological processes. NRP-1 is also expressed in a 
variety of cancers, suggesting a critical role in tumor progression. 
Increased levels of NRP-1 are correlated to tumor aggressiveness 
and are associated with poor prognosis. Graziani and Lacal review 
the role of NRP-1 in melanoma aggressiveness and the evidence 
supporting its use as target of therapies for metastatic melanoma.
An overview of the main immuno-oncology treatment strate-
gies that, either alone or in combination, are undergoing clinical 
development is provided by Ascierto et al. These include immu-
notherapeutic strategies that include adoptive transfer of ex vivo 
activated T cells, immunomodulatory monoclonal antibodies, 
and cancer vaccines. These focus on approaches being investi-
gated in the treatment of melanoma, which has been transformed 
by immunotherapy into a potentially curable disease.
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